PlainPharmaWatch

CMS Open Payments · Program Year 2024

Bridge to Life Ltd

Bridge to Life Ltd reported $5,620.68 across General Payments, Research, and Ownership to 9 physicians and teaching hospitals across 9 transactions.

$5.6K
All-tracks total
9
Transactions
9
Recipients
+$5.0K
General Payments vs PY2023

Bridge to Life Ltd reported $5,620.68 across all CMS Open Payments tracks (General + Research + Ownership) to 9 physicians and teaching hospitals in Program Year 2024 - ranking #1700 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $5,620.68, averaging $624.52 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer bridge-to-life-ltd Bridge to Life Ltd

$5.6K · #1700/1,925 · 0.0% industry · PY2024

  • TOT $5.6K
  • RANK #1700
  • SHARE 0.0%
  • TXN 9
  • RCP 9
  • CAT 2
  • GEN $5.6K
  • ΔGEN +$5.0K
  • TOP1 89.0%
  • PY 2024

Nearest volume peer: Rare Disease Therapeutics, Inc. ($5.6K)

Bridge to Life Ltd (this)$5.6KRare Disease Therapeutics, I…$5.6KKarl Storz Endovision, Inc.$5.5KGranata Bio Corporation$5.5KAquestive Therapeutics, Inc.$5.5K
All-tracks payment totals near Bridge to Life Ltd (CMS Open Payments PY2024)

Bridge to Life Ltd sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Bridge to Life Ltd's CMS-reported General Payments increased by $5.0K (+882.3%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2023: BRIDGE TO LIFE LTDPY2024: Bridge to Life Ltd. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$572.22PY2024$5.6K
PY2023
$572.22
PY2024
$5,620.68

What the Data Shows for Bridge to Life Ltd

In Program Year 2024, Bridge to Life Ltd reported $5,620.68 in payments to 9 physicians and teaching hospitals across 9 individual transactions, an average of $624.52 per transaction and $624.52 per recipient. That total places Bridge to Life Ltd at rank #1700 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

1 transactions worth $5.0K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 89.0% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 2 types of general payments, Bridge to Life Ltd's largest category was "Consulting Fee" at $5.0K - 89.0% of General Payments.

How Bridge to Life Ltd divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$5.0K2. Food and Beverage$620.68
Payment Type Amount Transactions
Consulting Fee $5.0K 1
Food and Beverage $620.68 8

Recipient Concentration in General Payments

The five largest recipient relationships account for $5,534.73 (98.5%) of $5,620.68 in this company's General Payments records across 6 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Bridge to Life Ltd

The five named recipients with the highest reported General Payments from this company

David a Axelrod$5.0KDaniel Lebovitz$271.79Garrett Roll$91.04Uwe Christians$85.95James Pomposelli$85.95
  1. 1

    David a Axelrod

    $5,000.00 across 1 reported transactions

  2. 2

    Daniel Lebovitz

    $271.79 across 4 reported transactions

  3. 3

    Garrett Roll

    $91.04 across 1 reported transactions

  4. 4

    Uwe Christians

    $85.95 across 1 reported transactions

  5. 5

    James Pomposelli

    $85.95 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Bridge to Life Ltd's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Bridge to Life Ltd.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Bridge to Life Ltd.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Bridge to Life Ltd's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.